Evidence-based toxicology for the 21st century: Opportunities and challenges

Altex

Volumn 30, Issue 1, 2013, Pages 74-103

  Stephens, Martin L ^a   Andersen, Melvin ^b   Becker, Richard A ^c   Betts, Kellyn ^d   Boekelheide, Kim ^e   Carney, Ed ^f   Chapin, Robert ^g   Devlin, Dennis ^h   Fitzpatrick, Suzanne ⁱ   Fowle, John R ^j   Harlow, Patricia ⁱ   Hartung, Thomas ^a   Hoffmann, Sebastian ^k   Holsapple, Michael ^l   Jacobs, Abigail ⁱ   Judson, Richard ^j   Naidenko, Olga ^m   Pastoor, Tim ⁿ   Patlewicz, Grace ^o   Rowan, Andrew ^p   Scherer, Roberta ^a   Shaikh, Rashid ^q   Simon, Ted ^r   Wolf, Douglas ^j   Zurlo, Joanne ^a   more..

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b HAMNER INSTITUTES FOR HEALTH SCIENCES   (United States)

^c American Chemistry Society   (United States)

^d Brown University ^*

^e BROWN UNIVERSITY   (United States)

^f DOW CHEMICAL COMPANY   (United States)

^g PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^h EXXONMOBIL UPSTREAM RESEARCH COMPANY   (United States)

ⁱ CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^j U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

^k services   (Germany)

^l BATTELLE MEMORIAL INSTITUTE   (United States)

^m Suite 100   (United States)

ⁿ SYNGENTA CROP PROTECTION   (United States)

^o DUPONT COMPANY   (United States)

^p Humane Society International   (United States)

^q Health Effects Institute   (United States)

^r Ted Simon LLC   (United States)

more..

Author keywords

Evidence based medicine; Evidence based toxicology; Systematic review; Test method assessment; Validation

Indexed keywords

ARTICLE; EVIDENCE BASED MEDICINE; EVIDENCE BASED TOXICOLOGY COLLABORATION; HEALTH CARE POLICY; MEDICAL SOCIETY; TOXICITY TESTING; TOXICOLOGY; UNITED STATES;

EID: 84873143423     PISSN: 1868596X     EISSN: 18688551     Source Type: Journal    
DOI: 10.14573/altex.2013.1.074     Document Type: Article

References (43)

1. Abhyankar, L. N., Jones, M. R., Guallar, E., et al. (2011). Arsenic exposure and hypertension: a systematic review. Environ Health Perspect 120, 494-500.
2. Adami, H.-O., Berry, C. L., Breckenridge, C. B., et al. (2011). Toxicology and epidemiology: improving the science with a framework for combining toxicological and epidemiological evidence to establish causal inference. Toxicol Sci 122, 223-234.
3. Bhattacharya, S., Zhang, Q., Carmichael, P., et al. (2011). Toxicity testing in the 21st century: defining new risk assessment approaches based on perturbations of intracellular toxicity pathways. PLoS ONE 6, e20887.
4. Biomarkers Definitions Working Group (2001). Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 69, 89-95.
5. Conrad, J. W. and Becker, R. A. (2010). Enhancing credibility of chemical safety studies: an emerging consensus on key assessment criteria. Environ Health Perspect 119, 757-764.
6. Covey, S. R. (1989). The Seven Habits of Highly Effective People: Restoring The Character Ethic. New York: Simon and Schuster.
7. Dieterle, F., Perentes, E., Cordier, A., et al. (2010a). Urinary clusterin, cystatin C, beta2-microglobulin and total protein as markers to detect drug-induced kidney injury. Nat Biotechnol 28, 463-469.
8. Dieterle, F., Sistare, F., Goodsaid, F., et al. (2010b). Renal biomarker qualification submission: a dialog between the FDAEMEA and Predictive Safety Testing Consortium. Nat Biotechnol 28, 455-462.
9. Griesinger, C., Hoffmann, S., Kinser, A., et al. (2009). Proceedings of the 1st international forum towards evidence-based toxicology. Preface. Hum Exp Toxicol 28, 83-86.
10. Guyatt, G., Cairns, J., Churchill, D., et al. (1992). Evidencebased medicine. A new approach to teaching the practice of medicine. JAMA 268, 2420-2425.
11. Guzelian, P. S., Victoroff, M. S., Halmes, N. C., et al. (2005). Evidence-based toxicology: a comprehensive framework for causation. Hum Exp Toxicol 24, 161-201. (Pubitemid 40778683)
12. Hamburg, M. (2011). Advancing regulatory science. Science 331, 987.
13. Harpur, E., Ennulat, D., Hoffman, D., et al. (2011). Biological qualification of biomarkers of chemical-induced renal toxicity in two strains of male rat. Toxicol Sci 122, 235-252.
14. Hartung, T. (2009). Food for thought ... on evidence-based toxicology. ALTEX 26, 75-82.
15. Hartung, T. (2010). Evidence-based toxicology -The toolbox of validation for the 21st century? ALTEX 27, 253-263.
16. Hoffmann, S. and Hartung, T. (2005). Diagnosis: toxic! -trying to apply approaches of clinical diagnostics and prevalence in toxicology considerations. Toxicol Sci 85, 422-428. (Pubitemid 40614273)
17. Hoffmann, S. and Hartung, T. (2006). Toward an evidencebased toxicology. Hum Exp Toxicol 25, 497-513.
18. Hoffmann, D., Adler, M., Vaidya, V. S., et al. (2010). Performance of novel kidney biomarkers in preclinical toxicity studies. Toxicol Sci 116, 8-22.
19. Hoffmann, S. (2012). Kick-off of the Evidence-based Toxicology Collaboration Europe. ALTEX 29, 456.
20. Hoffmann, S., Stephens, M. L., and Hartung, T. (in press). Evidence-based toxicology. Encyclopedia of Toxicology (3rd edition). Elsevier.
21. Jennings, C. A. (2006). Roberts Rules for Dummies. Hoboken: Wiley Publishing Company.
22. Judson, R., Kavlock, R., Martin, M., et al. (2013). Perspectives on validation of high-throughput assays supporting 21st century toxicity testing. ALTEX 30, 51-66.
23. Keller, D. A., Juberg, D. R., Catlin, N., et al. (2012). Identification and characterization of adverse effects in 21st century toxicology. Toxicol Sci 126, 291-297.
24. Kotter, J. P. (1996). Leading Change. Boston, MA: Harvard Business School Press.
25. Maull, E. A., Ahsan, H., Edwards, J., et al. (2012). Evaluation of the association between arsenic and diabetes: a National Toxicology Program workshop review. Environ Health Perspect 120, 1658-1670. http://dx.doi.org/10.1289/ehp. 1104579
26. Mayer, D. (2004). Essential Evidence-Based Medicine. New York: Cambridge University Press.
27. Navas-Acien, A., Silbergeld, E. K., Streeter, R. A., et al. (2006). Arsenic exposure and type 2 diabetes: A systematic review of the experimental and epidemiological evidence. Environ Health Perspect 114, 641-648.
28. Navas-Acien, A., Guallar, E., Silbergeld, E. K., et al. (2007). Lead exposure and cardiovascular disease: A systematic review. Environ Health Perspect 115, 472-482. (Pubitemid 46554449)
29. National Research Council -NRC (2007). Toxicity Testing in the 21st Century: A Vision and a Strategy. Washington D.C.: National Academies Press.
30. National Research Council (2011). Review of the Environmental Protection Agency's Draft IRIS Assessment of Formaldehyde. Washington, DC: National Academies Press. http://www.nap. edu/catalog/13142.html
31. Ozer, J. S., Dieterle, F., Troth, S., et al. (2010). A panel of urinary biomarkers to monitor reversibility of renal injury and a serum marker with improved potential to assess renal function. Nat Biotechnol 28, 486-494.
32. Schreider, J., Barrow, C., Birchfield, N., et al. (2010). Enhancing the credibility of decisions based on scientific conclusions: transparency is imperative. Toxicol Sci 116, 5-7.
33. Seed, J., Carney, E., Corley, R., et al. (2005). Overview: using mode of action and life stage information to evaluate the human relevance of animal toxicity data. Crit Rev Toxicol 35, 663-672. (Pubitemid 41693589)
34. Silbergeld, E. and Scherer, R. (2013). Evidence-based Toxicology: strait is the gate, but the road is worth taking. ALTEX 30, 67-73.
35. Starr, M. I. (2009). The origins, evolution and future of The Cochrance Database of Systematic Reviews. Int J Technol Assess Health Care 25, Suppl 1, 182-195.
36. Sutton, P., Woodruff, T. J., Vogel, S., et al. (2011). Conrad and Becker's "10 Criteria" fall short of addressing conflicts of interest in chemical safety studies. Environ Health Perspect 119, a506-A507.
37. US Food and Drug Administration (2010). Guidance for industry: qualification process for drug development tools. http://www.fda.gov/downloads/ Drugs/GuidanceComplianceRegu latoryInformation/Guidances/UCM230597.pdf
38. Vaidya, V. S., Ozer, J. S., Dieterle, F., et al. (2010). Kidney injury molecule-1 outperforms traditional biomarkers of kidney injury in preclinical biomarker qualification studies. Nat Biotechnol 28, 478-485.
39. Welytok, J. G. (2007). Nonprofit Law and Governance for Dummies. Hoboken, NJ: Wiley.
40. Woodcock, J., Buckman, S., Goodsaid, F., et al. (2011). Qualifying biomarkers for use in drug development: a U.S. Food and Drug Administration overview. Expert Opin Med Diagn 5, 369-374.
41. Woodruff, T. J., Sutton, P., and The Navigation Guide Work Group (2011). An evidence-based medicine methodology to bridge the gap between clinical and environmental health sciences. Health Affairs 30, 931-937.
42. Yu, Y., Jin, H., Holder, D., et al. (2010). Urinary biomarkers trefoil factor 3 and albumin enable early detection of kidney tubular injury. Nat Biotechnol 28, 470-477.
43. Zurlo, J. (2011). Evidence-based Toxicology Collaboration kick-off meeting. ALTEX 28, 151.